Fundraising Fox
/Companies
Sign in

Molecular Theranostics

Ohio, US · Founded 2014 · 1 known investors

Find your way into Molecular Theranostics

Sign up to see every warm intro you have to Molecular Theranostics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Molecular Theranostics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.

BiotechHealthtechMedical Devices

Founders & leadership

AC
Audrey Carballo

Investors · 1

Related companies · 2

UclahealthUCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.
MtemMolecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX. The company is no longer operating.

Companies working in the same space as Molecular Theranostics.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$265.2K
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$2.1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$249.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Molecular Theranostics do?
MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.
Who are Molecular Theranostics's investors?
Molecular Theranostics's investors include CWRU Technology Ventures.
Where is Molecular Theranostics headquartered?
Molecular Theranostics is headquartered in Ohio, US.